AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2021
Sep 14, 2021
32131_dirs_2021-09-14_50679243-670e-452b-ba9a-bb0f571410cd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-09-10
Reporting Person: Heyman Richard A. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-10 | Common Stock | S | 479 | $25.1005 | Disposed | 218261 | Indirect |
| 2021-09-13 | Common Stock | S | 601 | $25.0133 | Disposed | 217660 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 12500 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC.
F2: Represents the weighted average share price of an aggregate total of 479 shares sold in the price range of $25.05 to $25.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
F4: Represents the weighted average share price of an aggregate total of 601 shares sold in the price range of $25.00 to $25.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.